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Abstract: Extracellular adenosine triphosphate (eATP) is a potent molecule that has the capacity to modulate various 
aspects of cell functions including gene expression. This element of modulation is essential to the role of ATP as a 
therapeutic agent. The hypothesis presented is that ATP can have an important impact on the treatment of HIV infection. 
This is supported in part by published research, although a much greater role for ATP is suggested than prior authors ever 
thought possible. ATP has the ability to enhance the immune system and could thus improve the host’s own defense 
mechanisms to eradicate the virus-infected cells and restore normal immune function. This could provide effective 
therapy when used in conjunction with highly active antiretroviral therapies (HAART) to eliminate the latently infected 
cells. The key lies in applying ATP through the methodology described. This article presents a strategy for using ATP 
therapeutically along with background evidence to substantiate the importance of using ATP in the treatment of HIV 
infection. 
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OVERVIEW 
  The effect of the HIV virus on the immune system 
adversely affects homeostasis. Profound changes occur 
beyond enumeration of helper and suppressor T cells and 
viral levels. T regulatory cells (Tregs) heighten this 
dysfunction through their interactions with dendritic and 
other immune cells, resulting in suppression of the antigen 
presentation process. This type of activity points to cytokine, 
chemokine, and second messenger abnormalities leading to a 
greater degree of tolerance causing the immune system to 
operate pathologically. The interaction of eATP with cell 
surface receptors is well documented in the literature since 
the observations reported by Dr. Geoffrey Burnstock in 
1972[1]. The research initially focused on action potentials 
within the nervous system and has expanded to modulation 
of the vascular endothelium and the immune system cells 
leading to a loss or gain in function [2-4]. 
  ATP is a lipophobic molecule operating as a ligand that 
binds to receptors on the surface of cells and results in the 
manipulation of their function. Ectonucleotidase of CD39 
catalyzes ATP to adenosine diphosphate (ADP) and further 
to adenosine monophosphate (AMP), which CD73 (both 
membrane-bound and soluble forms) catalyzes to the final 
product of adenosine (ADO), with each metabolite exerting 
its own specific effects [5]. There is differential expression 
in both CD39 and CD73 between cell types where Foxp3+ 
Treg cells contain both, allowing for their participation in the 
complete hydrolysis of ATP to ADO (Fig. 1) [6-9]. This is 
considered a unique feature that defines Treg cell function by 
subduing an overactive immune response through the 
generation of ADO from ATP [7, 10]. CD39 expression is  
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identified to a high degree on a subset of Treg cells and is 
recognized to be a B cell activation marker. CD39 is 
expressed to a lesser degree on other hemopoetic cells 
including monocytes, dendritic cells, and natural killer (NK) 
cells and on activated T cells, erythrocytes, hepatocytes, and 
endothelial cells. 
  eATP interacts with the receptor types P2X1–P2X7 ion-
gated channels, affecting intracellular sodium, potassium, 
and calcium levels [11, 12]. The molecule has been shown to 
stimulate sodium influx into human lymphocytes by 3–12 
fold [13]. eATP opens permeablization pores of 900 Da in 
macrophages and 400 Da in lymphocytes, allowing small 
molecules to pass through the cell membrane [14]. 
Intracellular ionized free calcium is a signaling molecule that 
is kept tightly regulated between 10–200 nM concentrations, 
and oscillations in these levels result in changes in 
cytoskeletal protein rearrangements. eATP also binds to the 
P2Y family of transmembrane proteins embedded in the lipid 
bilayer [12]. P1 receptors with the subtypes of A(1), A(2A), 
A(2B), and A(3) are associated specifically with the 
interaction with ADO as well as with the down-regulation of 
immune responses [12]. All three of these major receptor 
pathways and their subtypes are involved in the signaling 
cascade that assists cells in recognizing and responding to 
their environment. Activation of the P1 receptor will likely 
further enhance the actions of eATP by resetting the stage. 
  eATP indirectly modulates cell function in several ways. 
One is through the tyrosine kinase receptor as a result of 
increasing the release of two growth factors: vascular 
endothelial growth factor (VEGF) and fibroblast growth 
factor (FGF2), both of which affect growth and 
differentiation [15-18]. eATP also modulates cell function 
indirectly through the nitric oxide (NO) pathway. NO is 
released from activated cells resulting in an increase of 
intracellular cyclic GMP (cGMP) in target cells. The 
consequences of these changes are measured in alterations in 210    Current HIV Research, 2011, Vol. 9, No. 4  Marc C.E. Wagner 
the expression of cytokines, chemokines, and second-
messenger molecules. Signal transduction initiated by eATP 
after binding to these receptors results in such actions as 
increasing phospholipase C and D [19-21]. The downstream 
effect of increasing phospholipase C is the cleaving of 
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 
triphosphate (IP3) and diacylglycerol (DAG), which in turn 
act as second messengers coordinating their efforts [22-25]. 
IP3 will lead to increased release of calcium from 
intracellular stores reacting with phosphokinase C (PKC). 
When PKC binds to DAG, it results in the phosphorylation 
of a myriad of proteins, which either turn on or turn off 
function. 
  When it interacts with the P2Y receptor, eATP has been 
shown to be involved in the regulation of glycogen 
metabolism through the activation of glycogen 
phosphorylase [26]. This action catalyzes the most accessible 
glucose found in glycogen stores, converting it to glucose-1-
phosphate and resulting in the release of energy quickly to 
the cell. The state of the organism determines how the 
changes will be interpreted. eATP affects mitogen-activated 
protein kinase (MAPK), which activates transcription factors 
likely through the binding of VEGF [27]. The activation of 
VEGF is considered to be a primary factor in angiogenesis, 
which is a direct effect of a tyrosine kinase 
autophosphorylation pathway lending to the support and 
creation of new blood vessels [15, 28]. eATP advances the 
activation of the kinase cascade via  ERK1/2 activating 
transcription factors through the activator protein 1 (AP-1) 
family, which leads to changes in cytokine and growth-factor 
expression. This validates the findings in the literature [29]. 
Cell proliferation is activated through this process. The 
resulting increase of intracellular free calcium concentration 
has been found to lead to the phosphorylation of ERK1/2 
[29]. Activation of the MAPK and the downstream ERK1/2 
pathways is thought to be necessary for NK cell lysis of 
tumor target cells and is required for NK effector function. 
Activation of these two pathways is involved in the 
regulation, mobilization, and distribution of cytoplasmic 
granules of granzyme B and perforin [30]. NK cell function 
is compromised by HIV infection. Enhancement of NK cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Binding of ATP to the P2X and P2Y series of receptors. ADP preferentially binds to the P2Y series of receptors. CD39 is involved 
in the catabolism of ATP to ADP to AMP. CD73 is involved in the catabolism of AMP to ADO. ADO preferentially binds to the P1 series of 
receptors. CD26 in association with adenosine deaminase metabolizes ADO to inosine which is further reduced by xanthine oxidase to uric 
acid. Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS  Current HIV Research, 2011, Vol. 9, No. 4    211 
function brought about by exposure to eATP could have a 
powerful effect on the elimination of the viral-infected cell 
[31]. 
  eATP also interacts with the P2Y G coupled protein 
receptors, eventually leading to increases in the level of 
intracellular cyclic AMP (cAMP) [32]. This pathway of 
transduction amplifies responses by the reversible protein 
phosphorylation of numerous cytosolic enzymes, driving many 
cellular actions such as the increase in adenosine 
monophosphate kinase (AMPK). Increasing AMPK leads to the 
phosphorylation of a number of proteins that act as metabolic 
masters attenuating glucose uptake and fatty acid metabolism 
[33]. It is important to note that any agent that would increase 
AMPK should yield a positive effect on type-2 diabetes [34]. 
  The increase in intracellular cAMP has a direct effect on 
protein kinase A (PKA), which belongs to the same family as 
protein kinases B and C (PKB, PKC). It is known in the 
literature that eATP activates PKA, PKB, and PKC [24, 32, 35]. 
In addition, the activation of PKA by prostaglandin E2 (PGE2) 
has been demonstrated to inhibit HIV-1 replication [36]. This 
effect is proposed to result in the down-regulation of the co-
binding receptor CCR5 [37]. Eicosanoids such as PGE2 are 
increased as a result of HIV infection over controls; this is 
perceived to be part of the disease process [38]. 
  The culmination of these advanced stages of cellular 
signaling is a cascade of molecular events yielding a change in 
cellular responsiveness. ATP binding to cell-surface 
purinergic receptors is responsible for relaying information 
from extracellular stimuli to the cell’s core regulatory 
mechanisms [39, 40]. Activation of PKC has been associated 
with proliferation, growth, differentiation, apoptosis, and the 
enhancement of the antigen-mediated T-cell activation. eATP 
induces the generation of neurotrophic factors such as FGF2, a 
potent angiogenic molecule that is also involved in tissue 
repair and the growth of smooth-muscle and hematopoetic 
cells. FGF2 may well work with VEGF in some of these 
actions, and CD39 may be associated in these responses. ATP 
released during injury activates epidermal growth factor 
receptors that enhance the healing process [41]. 
  Increased NO production acts as a potent vasodilator 
with an ability to increase intracellular cGMP [20]. NO 
protects the circulatory systems by decreasing blood pressure 
and lowering bad cholesterol levels; thus, in sufficient 
quantities, it improves cardiac function. Madhusoodanan and 
Murad demonstrated that nanomolar concentrations of NO 
would increase intracellular cGMP [42]. The real value may 
be in evaluating the ratios of cAMP to cGMP in subjects as 
ATP is applied clinically. In vitro, there appears to be a point 
at which increasing the dosage of eATP does not yield an 
increase in NO release from platelets [43]. This may reflect a 
saturation effect, a feedback mechanism, a state of 
equilibrium, or a product of desensitization. Desensitization 
is a fundamental example in homeostasis brought into play 
as a cell attempts to reach the basal state, which may be 
experienced in the clinical application. Desensitization has 
been identified in in vitro experiments as a natural 
phenomenon that can occur when a cell is exposed to eATP 
[44]. Endogenous sources of eATP are very small compared 
with the proposed application of this molecule, which leads 
to a differential effect exerted on immune system function. 
Exogenous treatment with ATP can achieve a broader and 
more substantial degree of change in immune activation, 
pushing the envelope of transformation. 
  The complexity of immune system function is rivaled by 
the complexity in eATP action [45]. The plasticity of the 
immune system can generate opposing effects –– in some 
cases inhibiting and in other cases strengthening particular 
actions. Thus more than one possibility or scenario can result 
from an action, yielding more than one conclusion. 
  The final outcome of the hydrolysis of ATP is ADO 
creating a type of ying-yang effect, which augments cellular 
responses as ADO down-regulates immune responses [19]. 
Being stimulatory, inhibitory, and/or bifunctional, eATP will 
exhibit the same range of potential yielding at times 
antagonistic roles. As an example, purinergic receptors are 
important players in both apoptosis and growth. eATP is a 
key physiologic molecule known to activate purinergic 
receptors, which are widely expressed among all cell types, 
triggering a cascade of downstream events with the inducible 
potential to cause cells of the immune system to alter 
function [46]. The activation of these receptors has a 
significant impact on cellular communication, adhesion, 
motility, proliferation, differentiation, development, death, 
regeneration, neurotransmission, and gene expression [47]. 
Increased eATP is currently thought to be associated with 
pathogenesis. A compelling and convincing argument can be 
made that eATP is more important in the repair process [15] 
[48]. 
  ATP initiates a pro-inflammatory response and is 
involved in the creation of inflammasones, representing a 
fundamental action that the innate immune system takes 
against an invading pathogen. ATP-induced autophagy of 
intracellular mycobacteria may overlap with this mechanism 
[49] [50] [51]. ADO, the downstream catalytic product of 
ATP, quiets the immune system. This sounding of the alarm 
and call to action by eATP, followed by the moderation 
imposed by ADO, represents a self-regulating system [52] 
[53]. eATP binding initiates signal transduction and results 
in transcription, translation, and second-messenger 
modulation that ultimately invokes a change in immune 
system action [54]. ATP orchestrates these changes on the 
HIV-infected immune system by altering how cells interact 
and react, leading to events such as the maturation of 
dendritic cells, the regulation of Tregs’ function, and an 
increased capacity for phagocytic activity. The culmination 
is a direct result of adjusting the level of expression and 
secretion of many cytokine, chemokine, and second-
messenger molecules. 
  eATP is emerging as a potent regulator of Treg function 
[55]. A subset of Treg cells known as Foxp3 + express high 
levels of CD39, potentially representing the inducible Tregs. 
The expression level of CD39 has been shown to be 
increased by cAMP, which results in an improved capacity 
for ATP to metabolize to AMP [56]. The presence of 
increased levels of eATP and/or its degradation products 
ADP, AMP, and ADO, acting through purinergic signaling, 
has been shown to alter the expression of these important 
effector molecules: IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
12, IL-18, IL-23, TNF-, thrombospondin-1, PGE2, 
prostacyclin, arachidonic acid, FGF2, VEGF, cAMP, cGMP, 
NO, and intracellular sodium, potassium, and calcium. 212    Current HIV Research, 2011, Vol. 9, No. 4  Marc C.E. Wagner 
 Table  1 itemizes the effect of eATP observed on each of 
these effector molecules and references the relevant research. 
The changes in these bio-molecules generated by ATP exert 
a significant effect on cells and on overall physiology 
because of the common language that cells use to 
communicate. The pattern of activation will vary by the 
target cell affected and by the role of each factor within the 
system as a whole. There exists an intimate relationship 
between these cellular communication molecules and how a 
cell functions that ultimately changes the outcome for the 
disease process in an individual. 
 
  There are over 30 trillion cells in the human body, each 
participating in a collaborative effort to reduce risk and allow 
for an individual to thrive. Proper communication between 
cells is essential for homeostasis. Dysfunction is 
characterized by something going wrong in the 
conversations between and among cells leading to a disease 
state. It is postulated here that all the bio-molecules altered 
by the presence of eATP work synergistically to bring about 
the improved health of the infected individual through 
modification of the communication biology. 
  It has been proposed in the literature that a duality of 
response that has been observed with eATP is concentration 
Table 1.  Modulation Effects of Extracellular ATP and Its Metabolites (Direct and Indirect on Cytokine and Second Messenger 
Expression 
 
Analyte Action  Source 
IL-1  Increased  [19, 60, 62, 134, 135] 
IL-1  Increased  [19, 60, 68, 70, 71, 74, 134, 136-139] 
IL-2 
Increased 
Decreased 
[48, 63, 140-142] 
IL-4 
Increased 
Decreased 
[108, 143] 
IL-6 
Increased 
Decreased 
[62, 108, 138, 144-148] 
IL-8  Increased  [19, 82, 149] 
IL10 
Increased 
Decreased 
[83, 103, 139, 142, 150-153] 
IL12 
Increased 
Decreased 
[19, 108, 112, 114, 139, 154, 155] 
IL-18  Increased  [68, 70, 71] 
IL-23 Increased  [19,  137] 
TNF- 
Increased 
Decreased 
[19, 136, 144, 150] [108, 136-140, 151, 155] 
Interferon   Increased  [63, 66, 136] 
Thrombospondin 1  Increased  [112, 115] 
Prostaglandin E2  Increased  [35, 151, 156] 
Prostacyclin  Increased  [23, 157, 158] 
Indoleamine 2-3 dioxygenase  Increased  [112, 115] 
Intracellular Sodium  Increased  [13] 
Intracellular Potassium 
Increased 
Decreased 
[68, 71] 
Intracellular Calcium 
Increased 
Decreased 
[14, 48, 70, 136, 137, 146, 157, 159-163] 
Cyclic AMP  Increased  [108, 114, 142, 154, 164, 165] 
Cyclic GMP  Increased  [20, 137] 
Nitric Oxide  Increased  [20, 43, 74, 137, 150, 157, 158] 
Prostaglandin D2  Increased  [23, 166] 
Thromboxane B2  Increased  [166] 
Arachidonic Acid  Increased  [23, 79, 82] Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS  Current HIV Research, 2011, Vol. 9, No. 4    213 
dependent. Low levels of eATP have been shown to inhibit 
platelet aggregation, while higher levels increase the 
potential for aggregation in vitro [57]. This dose-difference 
effect may result from the rate-limiting process of ATP 
catalyzing to AMP, where ADP is more prothrombotic [58]. 
ADP binding to either the P2Y1 or P2Y12 receptor on 
platelets leads to fibrinogen-receptor activation and 
contributes to platelet aggregation. The in vivo sources of 
eATP are associated with apoptosis or necrosis or are 
released from cells either through exocytosis or by shear 
force as occurs when red blood cells move through small 
veinules and arterioles [59]. Activated lymphocytes release 
ATP by means of exocytosis through the pannexin-1 
hemichannel, which acts as an autocrine stimulator and is 
thought to be crucial for effective activation of T cells, likely 
through the activation of PKC [2, 60, 61]. eATP might 
down-regulate Treg cells by up-regulating the secretion of 
IL-1 by activated macrophages and dendritic cells. The 
activation of the cysteine protease caspase – 1 converting 
enzyme is involved in the maturation and secretion of IL-1 
and IL-18 through the cleaving of the precursor forms. Upon 
secretion, IL-1  and IL-18 act as known anti-Treg cytokines 
shifting immune cells from a Th2 to a Th1 profile [62]. 
Caspase-1 is involved in the same manner in the processing 
of IL-23 and IL-33. 
  Treg cells are recognized as a pivotal component in 
immunosuppression with responsibility for inducing 
tolerance and controlling the activity of the immune system. 
Given what is known about the effects of eATP on cell 
physiology, one could anticipate in theory that IL-1 and IL-
12 released from macrophage or dendritic cells would share 
the ability to excite naïve T helper cells, enhancing their 
clonal expansion. One could also anticipate that the ensuing 
increase in IL-2 release would act in converting cytotoxic T 
cells into active killer cells and would cause B cells to 
transform into plasma cells, thus boosting immunoglobulin 
production specific to HIV antigens [63]. Activated B cells 
express high levels of CD39 correlating to their function. In 
combination with the naïve T helper cells, the release of IL-
12 from eATP-activated dendritic cells also induces the 
increased expression of gamma interferon (IFN-) as part of 
the gamma interferon axis that interfaces the innate and 
adaptive immune systems. The release of IL-18 promotes 
IFN- production by NK cells, which promotes naïve T 
helper cells into a Th1 profile. The increased secretion of IL-
18 exerts a suppressive action on Treg cell function. These 
responses represent critical countermeasures in the fight 
against invading pathogens. 
  Survival depends on the elimination of unnecessary or 
dangerous cells through more than one mechanism of cell 
death by apoptosis. This is a conventional process involved 
in normal tissue and organ maintenance. Diseases arise when 
this process becomes dysregulated [64]. Increased apoptosis 
is a hallmark of conditions such as HIV, Alzheimer’s, 
ischemic damage, and graft versus host disease to mention a 
few. This process has molecular mechanisms that are 
normally genetically regulated and kept in balance with Treg 
cells playing a crucial role. 
  HIV involves apoptosis of CD4 cells and limits the 
production of naïve T cells by inhibiting the process of 
renewal of immune competent cells. The inhibition of T-cell 
renewal is thought to result from the increased production of 
IL-7 induced by HIV infection [65]. Spranzi et al. evaluated 
eATP and found that it can trigger apoptosis and 
programmed cell death in human monocytic leukemia cells 
and certain tumor cell lines in culture following a rapid 
increase in intracellular calcium levels [66]. This group of 
researchers also found that the process of lysis was further 
enhanced in the presence of gamma interferon. This process 
was determined to be specific to eATP since the metabolites 
of ATP were unable to yield the same level of effect on 
apoptosis. Inhibitors of the calcium-binding protein 
calmodulin interrupted this process of apoptosis initiated by 
eATP. Thus calmodulin was linked as a target of change 
when a cell was treated with eATP. Calmodulin is known to 
activate over 20 different enzymes as part of its function. 
 Zheng  et al. further validated that eATP has the capacity 
to trigger apoptosis or induced programmed cell death in 
thymocytes, although the mechanism by which this happens 
has not been clearly identified [67]. Caspase-1 activation 
occurs when eATP binds to the P2X7 ion-gated channel 
triggering the process of apoptosis by means of a potent pro-
inflammatory response with the assembly of the 
inflammasome [68-70]. Subsequent stimulation of the P2X7 
receptor results in the efflux of potassium, causing the 
assembly of inactive, nucleotide-binding domain, leucine-
rich repeat proteins (NLRP3) with apoptosis-associated 
speck-like protein containing a CARD (ASC) and pro-
caspase-1. The activated inflammasome formed from this 
assemblage results in the maturation of IL-1, IL-18, IL-23, 
and IL-33 into their bioactive forms (Fig. 2) [71-73]. 
Endogenous eATP and uric acid can act as danger signals in 
initiating this type of response [74]. It is interesting to note 
that these two molecules denote the beginning and the end of 
the catalytic process. When eATP binds to the P2X7 
receptor, intracellular potassium concentration decreases, 
causing caspase-1 to switch from being a protective agent 
involved in enhancing cell survival to being the source of a 
suicide pathway determining cell fate by pyroptosis [75,76]. 
NF-B has been shown to be up-regulated upon eATP 
exposure  in vitro, which may contribute in the pro-
inflammatory apoptosis process [77]. 
  This reaction illustrates an efficient way for pathogens to 
be cleared by the innate immune system and highlights an 
important possible role for eATP in helping to eliminate 
latently infected cells [62, 78-80]. Quiescent cells latently 
infected with HIV, when activated by eATP, are more likely 
to undergo this host-beneficial process of inflammation that 
is defensive in nature and protective to the organism in 
clearing the infectious pathogen [81]. eATP aids in 
producing the find-me signal that promotes phagocytic 
clearance of apoptotic cells. This makes sense given that 
ATP would be released during the process of apoptosis. A 
two-part mechanism is involved that enhances the release of 
IL-8, which then escalates the movement of phagocytic cells 
toward the source in a sort of search-and-destroy mission 
[82]. It is a fascinating scenario. 
  NO is also involved in this process. When it is produced 
by macrophages via inducible nitric oxide synthase (iNOS), 
NO can induce apoptosis. When it is produced by endothelial 
cells  via  eNOS, however, NO is involved in regulating 
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via  the immune systems is a defense against pathogens. 
Upon stimulation with eATP, there is an increase in iNOS 
messenger ribonucleic acid (mRNA). This is stabilized by 
MAPK, favoring the production of NO [83]. NO and 
prostacyclin released by endothelial cells cause circulating 
platelets to remain inactive, reducing the potential for clot 
formation. eATP also enhances the production of 
superoxide, which represents a biologically toxic molecule 
and is produced by the immune system in an effort to fight 
invading pathogens [32,50]. 
  eATP binding to the P2X7 receptor has been shown to be 
involved in lymphocyte trafficking by promoting the 
shedding of CD23 and leukocyte-selectin (L-Selectin 
[CD62L]) [84,85]. Binding to P2YR subtypes, eATP can 
influence the migration and recruitment of immune cells, 
thus enhancing the immune response [86]. Chemokines, 
which are altered by eATP, assist in this process by which 
dendritic cells and T cells meet in lymphoid organs. The 
CCR5 chemokine receptor is down-regulated by eATP, 
while the CXCR4 receptor is up-regulated as a function of 
dendritic cell maturation [87,88]. The up-regulation of 
CXCR4 is likely due to the increase in intracellular cAMP. 
To a lesser extent than extracellular uridine triphosphate 
(eUTP), eATP has demonstrated a down-regulatory effect on 
CXCR4 [89]. This could have a significant effect on the 
entry of CCR5, CXCR4, and dual tropic viruses. eATP has 
demonstrated an ability to modulate selectins derived from 
endothelial cells (E-selectin), L-selectin, and platelet-selectin 
(P-selectin) [77]. Integrins are cell surface proteins that play 
a role in adherence to the extracellular matrix and are 
involved in transmembrane bi-directional signaling and are 
also affected by eATP, likely through oscillations in 
intracellular calcium levels [90]. These events can impact 
cell growth, survival, proliferation, adherence, and 
migration. 
  There are several reviews of the effects of eATP on 
cancer, which detail the majority of the research on ATP to 
date [91-93]. Even though this field of study was in its 
infancy in 1990, it was considered to be so meaningful that 
the Annals of the New York Academy of Sciences published a 
book at that time about the biological actions of eATP [94]. 
Purinergic Approaches in Experimental Therapeutics 
published in 1997 further explores this topic [95]. The 2010 
publication of Extracellular ATP and Adenosine as 
Regulators of Endothelial Cell Function, which focuses on 
several decades of research on the impact of eATP and ADO 
as regulators of endothelial cell function, affirms the 
continued importance of this area of study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Binding of ATP to the P2X receptor, which facilitates the efflux of K+ ions which causes the formation of the activated 
inflammasome. The inflammasome is responsible for the maturation of Pro IL-1, 18, 23, and 33 into their bioactive forms. Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS  Current HIV Research, 2011, Vol. 9, No. 4    215 
  There is abundant and widely accepted evidence in the 
literature documenting the cellular modulation capacity of 
eATP, which is at the core of its therapeutic potential [25, 
96-99]. Some controversy exists as to whether the effects 
resulting from eATP are a benefit and or a liability. The 
same is true for many bioactive molecules such as NO. 
  The administration of ATP for the treatment of diseases 
demands consideration and warrants additional research. The 
process of developing the hypothesis presented here has 
taken almost 20 years and continues to evolve. The proposed 
rationale has been the product of observation, review of the 
literature, understanding, and a vision of what could be 
achieved with the use of this molecule. For many years, there 
was considerable resistance in the scientific community to 
the idea that eATP was involved in cell communication 
[100]. Conventional wisdom suggested that ectonucleoti-
dases would quickly convert ATP to ADP, to AMP, and to 
ADO prior to eliciting a response. Indeed it was thought to 
be advantageous for cells to control the level of eATP since 
it has such a significant effect. Although the literature does 
support that hydrolysis occurs rapidly, it does not occur prior 
to receptor activation. Each of the metabolites of ATP exerts 
its specific effects. 
  Substantial advances have occurred in this field in the 
past 20 years, redefining and expanding the role of eATP in 
the modulation of cell function and its action on downstream 
targets. The time is right to pursue this inquiry to its full 
potential. As researchers, we need to remain open in our 
quest for the truth in order to be able to pick up on subtle 
clues that could lead to a fundamental increase in our 
understanding. The connection between eATP and the 
treatment of disease is not immediately obvious. This utility 
may provide the niche for ATP in the treatment of disease. 
Some of the evidence published in the literature supports the 
views presented here, but other evidence contradicts these 
views. This discrepancy is a function of the complexity of 
the immune systems’ components. ATP has been studied 
most often in single isolated system, and the results are 
subject to interpretation. 
A STRATEGY FOR THE THERAPEUTIC USE OF 
ATP 
  It is a well-accepted fact that eATP has broad effects on 
many cell systems. Following is a vision to apply this 
molecule in the way that will achieve the greatest results in 
the treatment of diseases involving the immune system. 
  It is essential to establish the right testing model. If the 
testing model is deficient, the answers may be accurate but 
the conclusions may be incomplete. An example of this with 
eATP can be seen in the murine model, which lacks the 
P2Y11 receptor that is coupled to adenylyl cyclase activation 
[101]. The best model to evaluate this hypothesis is believed 
to be in vivo, which holds all the diversity of cells types and 
biologically active molecules with which the virus is 
interacting on a daily basis. 
  Infection by HIV is a multistage process involving 
attachment, co-receptor binding, fusion, and entry of viral 
RNA into the T helper lymphocyte [102]. HIV is a non-
living virus on its own, yet it can integrate itself into the 
human CD4 cells and exploit the human system for the 
purpose of reproduction, with significant negative 
implications to the infected host. Treatment with anti-virals 
has led to the development of resistant strains, demonstrating 
the virus’s ability to evolve and adapt. 
  The biggest challenge in treating HIV infection is 
discovering how to eradicate the virus-infected cells. Even 
powerful HAART therapies have not been able to achieve 
this result. Latently infected cells remain unrecognized and 
untouched by the immune systems’ action. ATP has the 
potential to augment the fundamental function of the innate 
and adaptive immune systems to target the latently infected 
cells through activation, apoptosis, and subsequent removal. 
The co-administration of IFN- is expected to accelerate this 
process. In addition, nicotinamide adenine dinucleotide 
(NAD) may be added to increase the immune modulation 
[85]. In essence, ATP could revive normal immune function 
by altering the immunosuppressive reaction caused by the 
presence of the HIV virus shifting the balance of tolerance 
(Fig. 3) [103]. 
  The human system is an intricate biological machine 
composed of cells that interact in a sophisticated and 
eloquent way. Live cell imaging has provided a window by 
which many cell-to-cell interactions can be seen. Cells 
respond to environmental cues, and crosstalk is constant. 
Cytokines can be applied to cells, and their behavior can be 
observed. In the case of HIV, dendritic cells present the HIV 
antigens to naïve CD4 T cells for processing and interacting 
with other immune cells. Alterations in cytokines and 
second-messenger expression advance the action forward 
and modulate how cells respond to stimuli and cooperate 
with one another. The presence of the HIV virus changes 
these lines of communication over time, leading to a greater 
level of dysfunction within the host as evidenced by the 
switch from Th1 to Th2 cytokine expression as the infected 
individual moves into AIDS. This shift polarizes cells of the 
immune system towards tolerance. As a single 551-kD 
molecule, ATP has the ability to affect many of these 
parameters in an extraordinary manner. Its utility can be 
exploited in treating patients and ameliorating their condition 
through the restoration of this communication network. 
  The force of ATP on HIV is not directly antiviral. For an 
agent to be directly antiviral, it needs to interrupt the virus 
life cycle at some key point that can be evaluated in culture 
testing. ATP does not target specific points of viral 
production that can be adequately evaluated by culture 
means. This is further confirmed through the work of Barat 
et al. [88]. The effect of ATP on HIV is more indirect and 
will be found in its ability to change the microenvironment at 
the cellular level. The mechanism of these actions will vary 
depending on how the affected target cells address the 
commonality that exists in cellular processes being autocrine 
and/or paracrine in nature [100]. Regardless of how they do 
that, however, the affected target cells may in turn affect 
other cells both adjacent and at a distance through the 
cytokines/chemokines and second-messenger pathways. 
Some of the most important effects in this application are on 
the endothelial cells that line the blood vessels, the dendritic 
cells, and all the hematopoetic cells types [104]. ATP 
produces a different effect on each of these cell types [103, 
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  In 1994, Eliezer Rapaport published a significant article, 
“Utilization of ATP Administration for the Treatment of 
Cancer and AIDS”, which focused on cachexia, a common 
feature of the two diseases [107]. The mechanism of 
cachexia was believed to be related in large part to an 
increase in levels of tumor necrosis factor  (TNF-), which 
ATP had the ability to decrease. Dr. Rapaport did not 
recognize that ATP has a much greater role than 
counteracting physical wasting. The current understanding is 
that the A2A receptor binding of ADO is responsible for 
TNF- inhibition [108]. 
  The hypothesis presented here began with the idea in 
1991 of using purine and pyrimidine nucleosides and 
nucleotides as transport agents for the delivery of elements 
such as zinc and magnesium. This early work was referred to 
as NUC-ZM. It was observed that the nucleosides and 
nucleotides were suitable vehicles for chelated ions. 
Coordination sites exist where elements have a non-covalent 
association on the purine and pyrimidine bases [109]. The 
addition of zinc to double-stranded DNA increases the 
energy required to dissociate the two strands, thus adding 
additional stability to the DNA [110]. Others have described 
these chelates to be rather potent anti-ischemic agents, and 
observation of their effect confirmed that identification 
(unpublished observations). Eventually the focus of study 
moved to ATP as the core molecule with the greatest 
potential. Although its precursors have a place in science, the 
most significant value is found in the clinical application of 
ATP as the therapeutic agent. Oligonucleotides and 
polynucleotides of various lengths could also be expected to 
share some of the same pathways of induction if their 
sequence contains purines. Chemically modified purine 
nucleotides tri-, di-, and mono-phosphates can be utilized 
that may be less susceptible to degradation. However, ATP 
disodium is a safer form to use at least initially given its 
known safety profile. 
  The Drug Development and Clinical Sciences Branch of 
the National Institute of Allergy and Infectious Diseases 
provides a program to assist scientists in the evaluation of 
potential therapeutic agents for HIV. Dr. Steven Turk was 
approached in 1997 to assist in this evaluation by conducting 
testing on ATP along with adenine, ADO, and AMP in the 
established T-cell line CEM-SS infected with HIV-1RF or 
other cytolytic variants of HIV-1 or HIV-2. Drug efficacy 
and cytotoxicity were determined by the metabolic reduction 
of tetrazolium salt XTT. The purpose was to determine the 
antiviral drug activity against the cytolytic variants of HIV-
1RF. The results suggested no antiviral efficacy for adenine 
or ADO but some selective activity for ATP; the results for 
AMP were questionable because of solubility issues. The 
results were not impressive enough to warrant additional 
work on ATP or its precursors as a single-drug therapy. 
These were unpublished results. ATP is not postulated to 
have a direct antiviral effect. The hypothesis is centered on 
ATP’s immunomodulatory importance. Every cell in the 
immune system experiences its effects. 
  Bone marrow progenitor cells give rise to three distinct 
types of dendritic cells: langerhans, interstitial, and 
plasmacytoid, all of which possess an inherent adjuvant 
property [111]. These cells supply a link between the 
adaptive and innate immune processes, and are potent 
activators of both memory and naïve T cells. Altering the 
function of these cells can have an effect on inflammatory 
conditions such as the autoimmune disorders HIV/AIDS, 
Crohn’s disease, and ulcerative colitis. eATP influences 
dendritic cell maturation as part of its effect in up-regulating 
costimulatory and adhesion molecules of CD54, CD80, 
CD83, and CD86 [112,113]. Maturation initiated by eATP 
has been shown to coordinate the down-regulation of 
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inflammatory chemokine receptors CCR5 and CXCR4 on 
dendritic cells [114]. This reduces viral transmission to T 
helper cells. In chronic HIV infection, the level of CCR5 is 
up-regulated, which has a significant implication on the 
earliest point of HIV viral entry and disease persistence. 
Strains of HIV that are macrophage-tropic are not able to 
induce syncytia. There is evidence in the literature that eATP 
in culture affects the antigen presentation process between 
dendritic cells and CD4 cells, yielding a non-direct 
mechanism of anti-viral activity by increasing lysosomal 
degradation and decreasing the transfer of HIV to CD4+ 
lymphocytes [115]. Once again, changes in the expression of 
CCR5 are implicated. 
 Rizzo  et al. made the correlation between eATP and the 
immune response to inflammation that is dependent on time, 
and dose and possesses pro-inflammatory and anti-
inflammatory potential [116]. eATP has the ability to 
enhance immune action through the rapid release of pro-
inflammatory cytokines that favor the killing of pathogens. 
In addition, immune tolerance may be altered through 
thrombospondin-1, which is released in response to 
increased levels of eATP [112, 115, 117]. Crombie studied 
the anti-HIV effect of thrombospondin-1 and found that a 
10-fold increase in thrombospondin-1 in saliva was 
associated with decreasing HIV infectivity orally [117]. 
Taraboletti identified that thrombospondin-1 inhibits 
Kaposi’s sarcoma in HIV positive patients [118]. Kumar 
reviewed for the role of ADO as an endogenous modulator 
of the innate immune system with a therapeutic potential 
[119]. As discussed earlier, the catalytic process of ATP 
eventually leads to ADO. 
  To date, however, these issues have most often been 
studied in a one-dimensional culture environment. It is the 
contention here that the best testing model with a much 
broader dosage schedule is the more diverse system of an 
infected person. A human being has all the cell types that can 
be either directly or indirectly affected by increased levels of 
eATP. These cells and their actions work in concert with 
each other-not alone. 
  Cytokine expression can alter viral activity. Elevated 
expression of TNF- increases HIV viral replication [120] 
[121]. Decreasing a number of the pro-inflammatory 
cytokines such as TNF-, IL-4, and IL-6 along with 
increasing IL-10 can yield an antiviral effect. NO has been 
shown to be increased in patients with HIV-1 infection 
[122]. The biological responses observed after an individual 
becomes chronically infected with HIV can be seen as 
appropriate steps taken by the immune system in response to 
the viral infection, yet they fall short of being successful in 
eradicating the pathogen. This insufficient response is not 
beneficial overall with respect to the health of the infected 
individual, especially over time. It leaves the host ill 
equipped to respond to secondary infections as the immune 
system deteriorates. 
  The limited success of ATP in the clinical arena to date 
may be in part due to the lack of patentability other than use 
and to the fact that the most effective route of administration 
is by intravenous infusion. ATP can also be administered by 
intramuscular injection and orally, although it will likely 
require a much higher dosage when given intramuscularly or 
orally compared to intravenously. The application of ATP 
should not be overlooked since it can have a significant long-
term impact on the treatment of diseases related to abnormal 
tolerance. 
  ATP has been applied in the clinical setting in two 
completed trials for the treatment of cachexia in advanced 
cancer (stage IIIB and IV non-small cell lung cancer) [123-
125]. The focus of these two studies was to treat cachexia 
and improve quality of life performance scores in the patient 
population. The studies set out to demonstrate a positive 
effect on these two parameters, and they achieved that. The 
results did not demonstrate a decrease in tumor size or a 
notable increase in survival. Widespread apoptosis was not 
evidenced in the clinical trials as one might expect from the 
pre-clinical laboratory data. It may be that the results were 
stunted because of the choice of patients along with the 
dosage and the duration of treatment. This may have been 
the best population to demonstrate the anti-cachectic effect 
and improvement of Karnofsky scores but not the best given 
the other levels of dysfunction present. Nevertheless, these 
studies did demonstrate that ATP could be administered 
safely to patients. This is a very important step that now 
makes the application of ATP in the treatment of HIV more 
plausible. 
  Here is a single ancient molecule with vast potential: it is 
ubiquitous and can be used as a therapeutic agent. ATP 
offers an intriguing promise in the treatment of diseases. It 
will lessen the toxicity of chemotherapeutics and may best 
be applied as an adjuvant therapy just as proposed here for 
HIV [126]. ATP will work well in combination with other 
therapeutics for diseases such as cancer and HIV/AIDS 
yielding a one, two, three punch. 
  To ensure clinical success in the application of ATP, the 
dosage and duration of treatment should be tailored to meet 
the specific clinical needs of each patient. That will correlate 
with the greatest possible outcome. To date, a standard dose 
has been applied clinically to cancer patients: 50 micrograms 
per kilogram per minute over an 8-12 hour infusion in phase 
I and up to 96 hours in phase II. Researchers and clinicians 
are encouraged to think beyond the standard dose and 
schedule. Hitting the immune system with very high doses of 
ATP may not be necessary to achieve the desired outcome. 
A careful massaging may well be more desirable; an 
approach looking for the maximum efficacious dose may 
prove more effective as small changes can yield a dramatic 
impact. There can be considerable advantage in 
personalizing the dose and schedule to an individual’s 
clinical needs. The recommended way to do this is to 
establish disease-specific markers or repair markers for a 
given condition. In patients with HIV, the parameters to 
observe include CD4, CD8, quantitative proviral DNA, 
plasma viral RNA by PCR, neopterine, B2-microglobulin, 
IL-6, D-dimer, soluble IL-2, CD39 and CD73 expression, C-
reactive protein, uric acid, and adenosine deaminase. Other 
disease-specific markers may be appropriate and should be 
observed to evaluate the patient’s response to treatment, 
including any disease- or dysfunction-defining marker that is 
abnormal at baseline. 
  Start at 10 micrograms per kilogram per minute and 
increase or decrease the dosage as needed to achieve a 
maximum tolerable or maximum efficacious dose. If the 
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proposed dosage, discontinue therapy until any side effect 
abates and start again at half the original dosage followed by 
stepwise titration in dosage to reach the maximum tolerable 
or maximum efficacious dose. The maximum tolerable dose 
is defined as the highest amount that can be given without 
complication. The maximum efficacious dose is the point at 
which disease-specific markers are restored to normal. 
  Recent clinical trials of ATP did report adverse events in 
participants at the standard dose and schedule. The most 
common were chest pain and dyspnea, which resolved 
within minutes when ATP was discontinued. Another 
common complication was hyperuricemia, which was treated 
in study patients with allopurinol given along with ATP. 
Adenosine deaminase enzyme is essential in the catabolism 
of adenosine into 2’deoxyinosine and inosine, which is 
further catabolized into uric acid, a waste product at 
physiological pH. Uric acid exists as urate that is 30% 
excreted by the gastrointestinal tract and 70% via  renal 
excretions involving filtration, secretion, and post-secretory 
reabsorption at 6–10%. Normal purine nucleotide 
metabolism results in the production of uric acid leading to 
the hyperuricemia experienced in the clinical application of 
ATP; this is consistent with the known catalytic pathway for 
ATP [127-130]. Allopurinol inhibits the enzyme 
hypoxanthine oxidase and prevents the production of uric 
acid, thus favoring the salvage pathway making more 
nucleotides. The infusion of ATP should be continued until 
normal function is restored as assessed by markers. 
  The goal should be to revive normal cell function through 
a more structured application of ATP in vivo. One dose fits 
most will be less effective than tailoring the dosage and 
duration of treatment to meets the needs of the specific 
individual. It would be reasonable to expect that the level of 
response seen when a target cell is experiencing eATP would 
be concentration- and time-dependent, while prolonged 
stimulation by eATP may temporarily inactivate the 
receptors through a negative feedback loop. The response 
will likely vary due to factors such as the level of cell 
maturation, receptor expression and sensitivity, enzyme 
activity, and the degree of dysfunction present in the target 
cells at the time of treatment [131]. Even though this point 
may seem obvious, there is no evidence in the literature that 
anyone has attempted to apply ATP in the manner proposed 
here. 
  This methodology should be able to be applied in other 
diseases in an attempt to revive normal cell function by 
restoring the balance in tolerance. Conditions that could 
feasible be treated successfully following this methodology 
include those known to exhibit decreased levels of eATP 
such as type-2 diabetes, cystic fibrosis, and pulmonary 
hypertension as well as conditions involving a misdirected 
immune system such as type-1 diabetes, psoriasis, hepatitis 
A, B, and C, herpes, CMV, Epstein-Barr viral infections, 
tuberculosis, rheumatoid arthritis, Crohn’s disease, ulcerative 
colitis, asthma, and multiple sclerosis [132]. This mode of 
treatment will be useful in addressing the intersection of 
immune system activation, inflammation, and the process of 
chronic illness. There exists a strong connection among 
phagocytes, complement system, cytokines, and the 
coagulation systems, all of which are modulated by the 
presence of increased amounts of eATP. This is plausible 
given the array of effects ATP can elicit on these targets and 
its downstream effects. ATP alone can affect the immune 
system unlike any other single molecule. Once more is 
known about how to harness its beneficial properties, we 
may be able to substantially alter disease processes with the 
use of ATP [133]. 
  The foundation for this hypothesis rests on the work of 
many scientists such as Dr. Geoffrey Burnstock, Dr. Irshad 
H. Chaudry, Dr. Pieter C. Dagnelie, Dr. George Dubyak, Dr. 
Charles M. Haskell, and Dr. Eliezer Rapaport whose 
contributions built the framework and laid the initial 
groundwork detailing the various pathways altered by eATP. 
Their research has answered many questions, but many more 
need to be addressed. Knowledge constantly evolves, and the 
proposal put forth in this article represents another step in 
this process of understanding. Even though this hypothesis is 
not yet proven as fact, the basic science is already in place. 
Its benefits will not be fully appreciated until ATP is applied 
clinically and given proper scientific evaluation in an effort 
to explore the potential and limitations of this methodology. 
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